Completed PHASE3 NCT01421966

Evaluation of CureXcell® in Treating Lower Extremity Chronic Ulcers in Adults With Diabetes

A Phase III Multicenter, Randomized, Double-Blind, Parallel-Group, Sham-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Wound Care in Lower Extremity Chronic Ulcers in Adults With Diabetes Mellitus

Sponsor: ARANZ Medical

Conditions Lower Extremity Chronic Ulcers in Diabetics

Interventions CureXcell® Sham injection

Updated 7 times since 2017 Last updated: Dec 3, 2015 Started: Aug 31, 2011 Primary completion: Feb 28, 2015 Completion: Oct 31, 2015

Listed as NCT01421966, this PHASE3 trial focuses on Lower Extremity Chronic Ulcers in Diabetics and remains completed. Sponsored by ARANZ Medical, it has been updated 7 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Aug 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ARANZ Medical
Amarex Clinical Research
ICON plc
Macrocure Ltd.

Data source: Macrocure Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aiken, United States , Arlington Heights, United States , Boston, United States , Boucherville, Canada , Chicago, United States , Dallas, United States , Evans, United States , Fresno, United States , Glendale, United States , Greenville, United States and 27 more locations